Collaboration streamlines transition from first-in-human studies to proof-of-concept
Quotient Sciences, a global drug development, research, and manufacturing accelerator, and Biorasi, an international clinical research organization (CRO), today announced a strategic partnership to offer fully integrated early-phase clinical trial solutions. The collaboration is designed to help biotech and pharmaceutical sponsors accelerate programs from Investigational New Drug (IND) submissions to proof-of-concept (POC), seamlessly transitioning from healthy volunteers into patient populations within first-in-human (FIH) Phase I/IIa trials.
Streamlined, Single-Provider Model
Through this partnership, sponsors gain access to:
- Quotient Sciences’ clinical pharmacology expertise and facilities in Miami (US) and Nottingham (UK), encompassing 230 beds and a large participant database.
- Biorasi’s global patient recruitment network, spanning multiple therapeutic areas including dermatology, neurology, nephrology, cell therapy, and other specialty fields.
- A single contract and unified regulatory submissions, reducing outsourcing complexity and accelerating development timelines.
This integrated approach allows sponsors to conduct hybrid or multi-part protocols—combining healthy volunteer and patient cohorts within a single design—offering speed, flexibility, and scientific rigor while generating early clinical data efficiently.
Leadership Perspectives
Thierry Van Nieuwenhove, CEO of Quotient Sciences, said:
"This partnership reflects our 35-year commitment to accelerating drug development to Proof of Concept. By combining Quotient’s clinical expertise with Biorasi’s patient access network, we enable sponsors to conduct early-phase studies efficiently under a single operational model, while maintaining the highest standards of research and data quality."
Chris O’Brien, CEO of Biorasi, added:
"Biotech and pharma innovators need flexible, reliable solutions to succeed in today’s evolving clinical trial environment. Through this collaboration with Quotient Sciences, we provide sponsors with a simplified, scalable model supporting everything from FIH studies to patient POC, helping new therapies reach patients faster."
Translational Pharmaceutics® and Expanded Services
The collaboration builds on Quotient’s Translational Pharmaceutics®, a disruptive approach that integrates formulation development, drug product manufacturing, and clinical testing, saving up to 12 months and accelerating data-driven decision-making.
The partnership also expands access to adjacent services, including CDMO offerings such as pharmacy compounding, drug product manufacturing, data sciences, and regulatory support.
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the full development pathway. Recognized with CRO Leadership Awards (2021, 2022, 2024) and CDMO Leadership Awards (2023), Quotient helps sponsors bring molecules to patients faster by bridging silos across drug development capabilities.
About Biorasi
Biorasi is a global CRO delivering speed-to-market strategies for small to mid-sized biotech and biopharma sponsors. With over 20 years of experience, Biorasi operates across dermatology, oncology, neurology, nephrology, and other therapeutic areas, providing reliable, flexible, and accessible solutions for today’s complex clinical trial landscape.
